Zobrazeno 1 - 10
of 10
pro vyhledávání: '"M L, Vo Van"'
Autor:
M-L Vo Van, R Abbas, Y Zhao, D. Hershman, Sangeeta Gupta, Amy Freyman, L. Chow, Igor Bondarenko, Richard J. Epstein, Ahmad Awada
Publikováno v:
Cancer Research. 70:P3-14
Background: Neratinib (HKI-272), an irreversible inhibitor of the tyrosine kinase receptors Her1, -2 and -4, has shown antitumor activity in patients with Her2+ disease, with or without prior trastuzumab exposure. In preclinical models, neratinib inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b924c89261b68c50c6f47958851aab1f
https://doi.org/10.1158/0008-5472.sabcs10-p3-14-04
https://doi.org/10.1158/0008-5472.sabcs10-p3-14-04
Autor:
M-L Vo Van, Richat Abbas, T Luu, Binghe Xu, E. Staroslawska, V. Agrapart, A Berkenblit, Christine Powell, J Yang, Luis Manso, A Strahs, Véronique Diéras, L.Y. Dirix, Ahmad Awada
Publikováno v:
Cancer Research. 70:P3-14
Background: Neratinib (HKI-272) is an irreversible pan-ErbB tyrosine kinase inhibitor that blocks downstream signaling of the ErbB1, -2, and -4 receptors and has shown antitumor activity in patients with ErbB2+ breast cancer. Vinorelbine has shown sy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d89f065276aea29c5a96c1bcf4f0401
https://doi.org/10.1158/0008-5472.sabcs10-p3-14-05
https://doi.org/10.1158/0008-5472.sabcs10-p3-14-05
Autor:
Y Zhao, L W-C Chow, Binghe Xu, M-L Vo Van, Igor Bondarenko, Amy Freyman, Sangeeta Gupta, R Abbas
Publikováno v:
British Journal of Cancer
Introduction: Neratinib is a potent irreversible pan-ErbB tyrosine kinase inhibitor that has demonstrated antitumour activity and an acceptable safety profile in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c53662ad52a0b02a49932127d4f885e
https://pubmed.ncbi.nlm.nih.gov/23632474
https://pubmed.ncbi.nlm.nih.gov/23632474
Publikováno v:
Cancer Investigation. 11:135-139
Thirty patients with previously untreated and measurable or evaluable advanced soft tissue sarcoma entered this phase II study. Median age was 53 years (range: 24-71 years). Starting dose of Epirubicin was 100 mg/m2 IV bolus on day 1 combined with If
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa47c024c01681d368c65b4821940ca8
https://doi.org/10.3109/07357909309024831
https://doi.org/10.3109/07357909309024831
Autor:
J Mihura, P. Fargeot, Y. Devaux, M L Vo Van, M Mercier, P Fumoleau, S Schraub, M. Namer, P Kerbrat
Publikováno v:
Drugs. 45:38-45
Anthracyclines are among the most active drugs for the treatment of advanced breast cancer. Epirubicin has been found to be as effective as doxorubicin at equimolar doses but significantly better tolerated, especially in terms of alopecia, leucopenia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc96c0b104c6526deefdda2f44540427
https://doi.org/10.2165/00003495-199300452-00007
https://doi.org/10.2165/00003495-199300452-00007
Autor:
P, Fumoleau, Y, Devaux, M L, Vo Van, P, Kerbrat, P, Fargeot, S, Schraub, J, Mihura, M, Namer, M, Mercier
Publikováno v:
Drugs. 45
Anthracyclines are among the most active drugs for the treatment of advanced breast cancer. Epirubicin has been found to be as effective as doxorubicin at equimolar doses but significantly better tolerated, especially in terms of alopecia, leucopenia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::64ed0627b2700dc1e3d219178bdd41d3
https://pubmed.ncbi.nlm.nih.gov/7693420
https://pubmed.ncbi.nlm.nih.gov/7693420
Publikováno v:
Bulletin du cancer. 77(10)
Thirty-seven patients (pts) with previously untreated and measurable advanced soft tissue sarcoma entered this phase II study: 22 men and 15 women were included. Median age was 58 (range: 20-71). The starting dose of epirubicin was 100 mg/m2 IV bolus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::45b3a92e1b0003fa1d37ce2ceed997ef
https://pubmed.ncbi.nlm.nih.gov/2249019
https://pubmed.ncbi.nlm.nih.gov/2249019
Publikováno v:
Presse medicale (Paris, France : 1983). 13(23)
Twenty-five patients with prostatic carcinoma were involved in a Gehan's oriented phase II trial of D-Trp6-LH-RH in daily doses of 500 mcg for 7 days and 100 mcg for 3 months, this lapse of time being considered optimal for evaluation of the short-te
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::87733b31f1f0492ccde7e552f964b022
https://pubmed.ncbi.nlm.nih.gov/6233591
https://pubmed.ncbi.nlm.nih.gov/6233591
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.